


## CLAIMS

1. A compound of formula (1):



- 5 wherein R<sup>1</sup> is a -CH(CH<sub>3</sub>)<sub>2</sub>, -(CH<sub>2</sub>)<sub>2</sub>CH<sub>3</sub>, -CH<sub>2</sub>C(CH<sub>3</sub>)<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OH, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub>OCH<sub>3</sub>, -CH<sub>2</sub>CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>4</sub>O, -CH<sub>2</sub>CH<sub>2</sub>-N(CH<sub>2</sub>)<sub>4</sub>CH<sub>3</sub> or -CH<sub>2</sub>-CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub> group; and the salts, solvates and N-oxides thereof.
- 10 2. A compound according to Claim 1 which is 2-hydroxyethyl (2*S*)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate and the salts, solvates and N-oxides thereof.
- 15 3. A compound which is 2-hydroxyethyl (2*S*)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate.
- 20 4. A compound according to Claim 1 which is isopropyl (2*S*)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate and the salts, solvates and N-oxides thereof.
5. A compound which is isopropyl (2*S*)-2-(2-bromo-3-oxospiro[3.5]non-1-en-1-ylamino)-3-[4-([2,7]naphthyridin-1-ylamino)phenyl]propanoate.

6. A pharmaceutical composition comprising a compound according to any one of Claims 1 to 5 together with one or more pharmaceutically acceptable carriers, excipients or diluents.